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Abstract Background: The reported remission of type 2 diabetes in patients undergoing Roux-en-Y gastric
bypass has brought the role of the gut in glucose metabolism into focus. Our objective was to
explore the differential effects on glucose homeostasis after oral versus gastrostomy glucose loading
in patients with Roux-en-Y gastric bypass at an academic health science center.
Methods: A comparative controlled investigation of oral versus gastrostomy glucose loading in 5
patients who had previously undergone gastric bypass and had a gastrostomy tube placed in the
gastric remnant for feeding. A standard glucose load was administered either orally (day 1) or by the
gastrostomy tube (day 2). The plasma levels of glucose, insulin, glucagon-like peptide 1 and peptide
YY were measured before and after glucose loading.
Results: Exclusion of the proximal small bowel from glucose passage induced greater plasma
insulin, glucagon-like peptide 1, and peptide YY responses compared with glucose loading by way
of the gastrostomy tube (P .05).
Conclusions: Exclusion of glucose passage through the proximal small bowel results in enhanced
insulin and gut hormone responses in patients after gastric bypass. The gut plays a central role in
glucose metabolism and represents a target for future antidiabetes therapies. (Surg Obes Relat Dis
2012;8:371–374.) © 2012 American Society for Metabolic and Bariatric Surgery. All rights
reserved.
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Surgery for Obesity and Related Diseases 8 (2012) 371–374like peptide 1; GLP-1Roux-en-Y gastric bypass improves glycemic control
within days [1,2]. The initial increased insulin secretion and
reduced insulin resistance appears to be independent of weight
loss [3]. Increased glucagon-like peptide 1 (GLP-1) levels after
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1550-7289/12/$ – see front matter © 2012 American Society for Metabolic and
doi:10.1016/j.soard.2012.01.021gastric bypass are associated with increased insulin secretion
but not reduced insulin resistance [1]. These findings, together
with experiments on animal models, have brought the gut’s
role in glucose homeostasis into focus and novel endoluminal
devices have been introduced in an attempt to mimic the
metabolic effects of gastric bypass [4–6]. A remaining conun-
drum is the rapid weight loss and weight loss maintenance after
gastric bypass, making it challenging to confirm the hypothesis
that the effects on glycemic control are indeed weight loss
independent. The aim of the present study was to investigate
the effect of glucose loading into different gut segments in
weight stable patients who have had their type 2 diabetes
placed into remission after gastric bypass.
Bariatric Surgery. All rights reserved.
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372 D. J. Pournaras et al. / Surgery for Obesity and Related Diseases 8 (2012) 371–374Methods
The study was approved by the Clinical Governance and
Patient Safety Committee of Imperial College Healthcare
National Health Service Trust (reference number 10/807)
and was performed according to the Declaration of Helsinki.
The 5 patients who had undergone gastric bypass provided
informed consent. Surgery was performed as previously
described [7]. All participants had had type 2 diabetes pre-
peratively and had had achieved normoglycemia without
equiring any hypoglycemic medication by the time of the
tudy. The mean body weight loss was 29.9%  4.6%
resulting in a body mass index reduction from 43.2 1.9 to
29.9  2.4 kg/m2 (P  .001). Because of surgical compli-
ations, the patients had been unable to maintain adequate
alorie intake. To allow for enteral feeding, all patients had
een provided with a functioning gastrostomy tube. The
atients were treated conservatively or surgically and had
ully recovered so that at the time of testing (14 4 months
ostoperatively, range 9–24), all patients had normal nutri-
ion status, tolerated oral liquids, and had a stable body
eight.
All examinations were performed at 8 AM after an over-
ight fast on 2 different days 3–6 days apart. A 410-mL
olution containing 75 g glucose, 287 kcal (Lucozade En-
rgy Original, GlaxoSmithKline, Middlesex, United King-
om) was given orally on day 1 (to verify the patients could
olerate the volume orally) and by gastrostomy on the sec-
nd occasion. The duration of the solution administration
as 10 minutes on both days. A schematic illustration of the
astrointestinal glucose route after oral and gastrostomy
oading is given in Figure 1. Blood was obtained by a
enous catheter using tubes containing ethylenediaminetet-
aacetic acid and aprotinin before and 15, 30, 60, 90, 120,
50, and 180 minutes after glucose loading. The samples
ere stored and peptide YY (PYY)-like immunoreactivity
full length, PYY1–36, and fragment, PYY3–36) and
lasma total GLP-1 were measured, as previously described
8–10]. Gastric inhibitory polypeptide (GIP) was measured
sing enzyme-linked immunosorbent assay (Millipore, Bil-
Fig. 1. Schematic illustration of gastrointestinal glucose route after oral
(black arrows) and after gastrostomy load (empty arrows).erica, MA). Glucagon was measured by an in-house radio-
mmunoassay [11]. Glucose was measured with an auto-
ated glucose analyzer (Abbott Laboratories, Chicago, IL),
nd insulin was measured with an automated chemilumi-
escent immunoassay (Abbott Laboratories, Chicago, IL).
The results were analyzed using GraphPad Prism, ver-
ion 5.00, for Windows (GraphPad Software, San Diego,
A). The data are presented as the mean  SEM. The
lasma levels of insulin, GLP-1, PYY, GIP, glucagon and
lucose after the 2 glucose loadings were analyzed with a
-way group (between subjects)  time (within subjects)
nalysis of variance, presented with the F test, and the
umbers in parentheses are the degrees of freedom. Post hoc
onferroni tests for each concentration were applied when
here was a significant group  time interaction. P .05
as considered significant.
esults
Figure 2 shows the plasma levels of glucose, insulin,
LP-1, PYY, GIP, and glucagon after oral and gastrostomy
lucose loading. Two-way analysis of variance revealed a
ignificant difference in plasma insulin, GLP-1, and PYY
all P .01) levels between the oral and gastrostomy glu-
cose loading. There was also a significant main effect of
time and a significant group  time interaction for insulin,
LP-1, and PYY (all P .001). The patients returned more
uickly to the baseline glucose levels after oral glucose
oading compared to patients who had received the glucose
oad by gastrostomy (P .001), with a significant group 
ime interaction (P .001) but no significant main group
ffect for glucose levels (P  .84).
No difference was found in the GIP postprandial re-
ponse between the 2 routes used. The glucagon postpran-
ial response was greater with the oral route (2-way
nalysis of variance, P .01); however, there was no
ignificant effect of time and group  time interaction.
The values of the 2-way analysis of variance for glucose,
insulin, GLP-1, PYY, GIP, and glucagon are summarized
in Table 1.
Discussion
The present study has demonstrated that an altered de-
livery of nutrients to the intestine, which excludes the prox-
imal gut, results in improved postprandial glucose handling.
In particular, excluding the distal stomach, duodenum, and
proximal jejunum from nutrient transit reduces the duration
of hyperglycemia and leads to enhanced insulin, incretin,
and satiety gut hormone responses after glucose loading. In
contrast, in weight stable patients, the restoration of the
duodenal passage after gastric bypass by gastrostomy
increases the duration of hyperglycemia and attenuates
the incretin and insulin responses to glucose. Our obser-
vations support the hypothesis that endocrine changes
t P .00
T
T
t
373Proximal Small Bowel and Glycemic Control / Surgery for Obesity and Related Diseases 8 (2012) 371–374play an important role in the improvement of diabetes
after gastrointestinal bypass surgery [3,4,12–18]. How-
ever, differentiating between the relative contribution of
proximal versus distal small gut signals to glycemic con-
trol was outside the purpose of the present study.
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Fig. 2. Plasma levels of (A) glucose, (B) insulin, (C) GLP-1, and (D) PYY,
glucose load. Data presented as mean values  SEM. When 2-way analysi
est was used for point to point analysis between 2 groups (*P .05, ***
able 1
wo-way analysis of variance values (F test, numbers in parentheses are
ube glucose load as a function of group and time
Variable Time
Glucose F(7,57)  5.81; P .001
Insulin F(7,57)  7.64; P .001
GLP-1 F(7,58)  10.51; P .001
PYY F(7,58)  8.79; P .001
GIP F(6,43)  3.98; P  .003
Glucagon F(4,30)  1.98; P  .12GLP-1  glucagon-like peptide 1; PYY  peptide YY; GIP  gastric inhibitExclusion of the duodenum and jejunum in Goto-Kak-
izaki, spontaneously nonobese type 2 diabetic rats, can have
a weight loss-independent effect on type 2 diabetes, sug-
gesting that the proximal gut might be implicated in the
pathogenesis of the disease [4,19]. Glucose tolerance was
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, and (F) glucagon after oral (black circles) and gastrostomy (open circles)
iance revealed a significant group  time interaction, post hoc Bonferroni
1).
of freedom) for comparison of gut hormones after oral and gastrostomy
roup Time  group
1,57)  0.04; P  .84 F(7;57)  4.26; P .001
1,57)  8.88; P  .004 F(7,57)  5.87; P .001
1,58)  32.08; P .001 F(7,58)  9.10; P .001
1,58)  96.77; P .001 F(7,58)  7.61; P .001
1,43)  0.59; P  .45 F(6,43)  0.52; P  .79
1,30)  7.88; P  .0087 F(4,30)  1.12; P  .360
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374 D. J. Pournaras et al. / Surgery for Obesity and Related Diseases 8 (2012) 371–374markedly improved postoperatively. Furthermore, in an an-
other study of the same type of rats, duodenojejunal bypass
led to the improvement of oral glucose tolerance in contrast
to gastrojejunostomy, which had no effect [4]. Exclusion of
the duodenum by reoperation of the rats with gastrojejunos-
tomy improved glucose tolerance, and restoration of the
duodenal passage in rats that had undergone duodenojejunal
bypass caused the recurrence of impaired glucose tolerance
[4]. The available human data supporting the weight loss-
independent effect of Roux-en-Y gastric bypass on glucose
homeostasis and the “foregut hypothesis” are limited.
GIP responses after gastric bypass remain controversial,
with most investigators showing a decrease [16], but others
showing an increase [15]. We did not find a significant
difference in our study, but our experiment was not powered
to detect a difference in GIP.
A single case has been reported in which nutrient stim-
ulation by oral feeding was compared with gastric tube
feeding in a patient after gastric bypass [20]. However, by
repeating the experiments in a series of weight stable pa-
tients in whom diabetes had gone into remission, we have
shown a consistent threefold elevation of insulin, GLP-1,
and PYY after oral glucose loading. Dirksen et al. [20] have
also demonstrated no overall difference in GIP or glucagon,
consistent with the result of our study.
One limitation of our study was the nonrandom alloca-
tion of oral and gastrostomy days; however, we had to
ensure that the patients could tolerate the volume orally,
before administering it through the gastrostomy tube. More-
over, each patient served as their own control, and all tests
were performed within a 3–6-day period.
Conclusions
Exclusion of the proximal small gut by gastric bypass
surgery resulted in weight-independent modifications of gut
hormones and glucose homeostasis. Understanding the
mechanisms by which gastric bypass alters the metabolism
might lead to novel devices or therapeutic approaches for
the treatment of type 2 diabetes.
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